Elsevier

Immunology Letters

Volume 86, Issue 2, 3 April 2003, Pages 123-129
Immunology Letters

Review
IL-10, an inflammatory/inhibitory cytokine, but not always

https://doi.org/10.1016/S0165-2478(03)00002-6Get rights and content

Abstract

IL-10 has been previously called cytokine synthesis inhibiting factor, produced mostly by Th2 cells, macrophages and CD8+ cell clones. IL-10 is capable of inhibiting the synthesis of several cytokines from different cells, antigen or mitogen activated. IL-10 exerts its inhibition at the mRNA transcriptional and translational level. In addition, IL-10 is a co-stimulatory cytokine on activated T cells. For example, IL-10 inhibits NK cell activity, the production of Th1 cytokines, cytokines generated by peripheral blood mononuclear cells, and macrophage activity. On the other hand, IL-10 exerts immunostimulatory effects on B cells, cytotoxic T cell development and thymocytes. In mast cells derived from CD4+/CD133+ cells, IL-10 inhibits IL-6 and TNFα, and prostaglandin E1 and E2 induced by IL-6. Here, we report for the first time that IL-10 fails to inhibit tryptase and IL-6 from human mast cell-1 (HMC-1) and human umbilical cord blood-derived mast cells.

Section snippets

IL-10 and mast cells

Activated mast cells through their high affinity IgE receptors (FcεRI) produce diverse preformed granule mediators, such as histamine and proteinases as well as a wide variety of pro-inflammatory cytokines (Fig. 3) [26], [27], [28]. IL-10 alone fails to support the growth of mast cell lines and mast cell progenitors [29], but significantly enhances the growth activity of stem cell factor (SCF) [30]. IL-10 in combination with other cytokines is optimal for mast cell development from cord blood

Acknowledgements

The authors are indebted to Neopharmed, an Italian entity of Merck & Co., Withehouse Station, NJ, USA for their financial support.

References (48)

  • P.P. Wang et al.

    J. Biol. Chem.

    (1995)
  • J.M. Lu-Kuo et al.

    J. Biol. Chem.

    (1996)
  • P. Conti et al.

    Blood

    (1997)
  • P. Conti et al.

    Immunol. Lett.

    (1997)
  • T.R. Mossman et al.

    Ann. Rev. Immunol.

    (1989)
  • K.W. Moore et al.

    Ann. Rev. Immunol.

    (2001)
  • H. Spits et al.

    Int. Arch. Allergy Immunol.

    (1992)
  • K. Wolk et al.

    J. Immunol.

    (2002)
  • R. Lang et al.

    J. Immunol.

    (2002)
  • S.V. Kotenko et al.

    Oncogene

    (2000)
  • K.W. Moore et al.

    Science

    (1990)
  • S. Kasahara et al.

    Int. J. Immunopathol. Pharmacol.

    (2001)
  • S. Yoshino et al.

    Int. J. Immunopathol. Pharmacol.

    (2002)
  • A. Perrella et al.

    Int. J. Immunopathol. Pharmacol.

    (2001)
  • I.B. McInnes et al.

    J. Immunol.

    (2001)
  • A. Denys et al.

    J. Immunol.

    (2002)
  • A. Byrne et al.

    J. Immunol.

    (2002)
  • Y. Levy et al.

    J. Clin. Invest.

    (1994)
  • A. Conforti et al.

    Int. J. Immunopathol. Pharmacol.

    (2001)
  • S. Corinti et al.

    J. Immunol.

    (2001)
  • B.J. Prakken et al.

    J. Immunol.

    (2001)
  • R. de Waal Malefyt et al.

    J. Exp. Med.

    (1991)
  • S. Hashimoto et al.

    J. Immunol.

    (2001)
  • J.P. Palma et al.

    J. Immunol.

    (2002)
  • Cited by (195)

    • Multifunctional hydrogel modulates the immune microenvironment to improve allogeneic spinal cord tissue survival for complete spinal cord injury repair

      2023, Acta Biomaterialia
      Citation Excerpt :

      To improve the inflammatory regulation effects, interleukin (IL)-10 was added to the gelatin-based hydrogel [18]. IL-10 is an inflammatory and immunosuppressive factor that plays a role in infection, inflammation, and organ transplantation [19,20]. It is mainly produced by T helper 2 (Th2) cells, macrophages, and CD8+ cell clones.

    View all citing articles on Scopus
    View full text